Difference between revisions of "Citalopram-agomelatine"
From Psychiatrienet
| (22 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | {{ | + | {{ Drugswitchago |
| from = citalopram | | from = citalopram | ||
| to = agomelatine | | to = agomelatine | ||
| stop = | | stop = | ||
| − | + | {{TCAdecrease25p3d}} | |
| − | |||
| − | |||
| − | | start = | + | | start = {{StartAgomelatine}} |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
}} | }} | ||
Latest revision as of 11:00, 4 August 2023
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from citalopram to agomelatine.[1] [2] [3]
Stop citalopram - Day 1: Decrease with about 25% of the original dose per 3 days.
Start agomelatine- Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.[4]
- If necessary, increase dosage of agomelatine to 50 mg/day.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ CBG meb, accessed august 2023,SmPC Valdoxan
- ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
